CLINICAL ONCOLOGY PROGRAM

临床肿瘤学项目

• 批准号: 2088844
• 负责人: James D Bearden
• 金额: $ 14.02万
• 依托单位: SPARTANBURG REGIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 1996-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2088844
• 关键词: 13 cis retinoate; Hodgkin's disease; acute leukemia; acute lymphocytic leukemia; adenocarcinoma; antineoplastics; behavioral medicine; biomarker; bladder neoplasm; bleomycin; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cancer rehabilitation /care; cancer risk; cervix neoplasms; chemoprevention; cis platinum compound; clinical trials; colorectal neoplasms; combination chemotherapy; community health services; continuing education; cooperative study; cyclophosphamide; cystectomy; cytogenetics; cytosine arabinoside; dacarbazine; daunorubicin; doxorubicin; early diagnosis; etoposide; flow cytometry; fluorouracil; germ cell neoplasms; head /neck neoplasm; human subject; human therapy evaluation; hydroxyurea; ifosfamide; interferons; leucovorin; levamisole; lomustine; lung neoplasms; lymphoma; mammography; mechlorethamine; melanoma; methotrexate; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer nutrition therapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nutrition related tag; oral leukoplakia; ovary neoplasms; paclitaxel; pancreas neoplasms; patient /disease registry; patient care management; peptide hormone analog; pharmacy administration; prednisone; primary care physician; procarbazine; prostate neoplasms; quality of life; regional medical planning; relaxation; small cell lung cancer; smoking cessation; tamoxifen; testis neoplasms; tocopherols; trimetrexate; vincristine

The Spartanburg Community Clinical Oncology Program (SCCOP) has been an enthusiastic participant in the CCOP program since its inception. Since 1983 SCCOP has accrued greater than 10% of all newly diagnosed cancer patients in our regional tumor registry to cancer treatment protocols with data of high quality and low cost per accrual in this rural CCOP. The average accrual per year of 102 compares favorably with the average yearly treatment accrual CCOP wide of 86 as stated in the RFA. The SCCOP accrued 100 subjects to cancer control protocols in FY-06, equivalent to the average accrual CCOP wide of 109.6 subjects per year as stated in the RFA. SCCOP believes that participation in NCI approved cancer treatment and cancer control protocol activities is an ideal way to bring state-of-the- art cancer treatment and cancer control research to members of our community and involve a wider segment of our community in such activities. This participation will transfer newly developed technology in cancer prevention, early detection, treatment, patient management, rehabilitation and continuing care to our community in an accelerated fashion and correspondingly reduce cancer incidence, morbidity and mortality. The goals of the SCCOP for this grant period are to maintain and expand our cancer treatment accruals and to develop a comprehensive cancer control trials program. This will be accomplished by enlisting a larger number of subspecialty investigators (ENT, urology, surgical oncology, gynecology) in cancer treatment and cancer control activities, and encompassing both the family practice residency program at Spartanburg Regional Medical Center and private practice primary care physicians in cancer control activities. The SCCOP will continue to affiliate with SWOG, CCWFU, NSABP, and MDACC as research bases. The grant will support three full-time equivalents for data management. The consortium hospitals, as a measure of their commitment to the CCOP program, are providing significant funding for one FTE (secretary/data manager) and additional funds for travel and cancer control data management activities. The SCCOP enthusiastically recompetes at this time for continued funding for an activity which has proven extremely rewarding for this community.

斯巴达堡社区临床肿瘤学计划（SCCOP）一直是 自成立以来，CCOP计划的热情参与者。 自从 1983年，SCCOP累积了所有已诊断出的癌症的10％以上 我们区域肿瘤注册表中癌症治疗方案的患者 在此农村CCOP中，高质量和低成本的数据。 这 每年的平均应计102与平均年度相比 如RFA所述，处理量为86的CCOP。 SCCOP在06财年中获得了100名癌症控制方案的受试者， 相当于每年的平均应计CCOP宽109.6受试者 在RFA中说明。 SCCOP认为参加NCI批准的癌症治疗和 癌症控制方案活动是带来最新的理想方式 艺术癌症治疗和癌症控制研究给我们的成员 社区，涉及我们社区的更广泛的活动。 这种参与将转移新开发的癌症技术 预防，早期检测，治疗，患者管理，康复 并以加速的方式继续向我们的社区照顾 相应地降低癌症的发生率，发病率和死亡率。 在此赠款期间，SCCOP的目标是维护和扩展我们 癌症治疗累计并发展全面的癌症控制 试验计划。 这将通过招募更多数量来实现 专科研究人员（泌尿外科，外科肿瘤学，妇科） 癌症治疗和癌症控制活动，并包括 斯巴达堡地区医疗中心的家庭实践居住计划 以及癌症控制活动的私人执业初级保健医生。 SCCOP将继续与Swog，CCWFU，NSABP和MDACC相关联 研究基础。 该赠款将支持三个全职等价物 数据管理。 财团医院，以衡量他们 对CCOP计划的承诺，为一个人提供了大量资金 FTE（秘书/数据经理）和旅行和癌症的额外资金 控制数据管理活动。 此时，SCCOP热情地卷土切实 对于这一对这个社区非常有益的活动。